KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Cash (2016 - 2025)

Historic Change in Cash for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $4.4 million.

  • Acadia Pharmaceuticals' Change in Cash rose 12296.02% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.5 million, marking a year-over-year increase of 7270.67%. This contributed to the annual value of $133.9 million for FY2024, which is 8145.26% up from last year.
  • Acadia Pharmaceuticals' Change in Cash amounted to $4.4 million in Q3 2025, which was up 12296.02% from $36.6 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Change in Cash peaked at $176.0 million during Q1 2023, and registered a low of -$180.6 million during Q2 2023.
  • For the 5-year period, Acadia Pharmaceuticals' Change in Cash averaged around -$3.4 million, with its median value being -$12.1 million (2023).
  • In the last 5 years, Acadia Pharmaceuticals' Change in Cash surged by 36686.32% in 2022 and then plummeted by 73334.78% in 2025.
  • Acadia Pharmaceuticals' Change in Cash (Quarter) stood at $52.8 million in 2021, then crashed by 175.76% to -$40.0 million in 2022, then soared by 326.18% to $90.5 million in 2023, then soared by 81.77% to $164.4 million in 2024, then tumbled by 97.35% to $4.4 million in 2025.
  • Its Change in Cash was $4.4 million in Q3 2025, compared to $36.6 million in Q2 2025 and -$101.9 million in Q1 2025.